title: A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.
abstract: The past decade has seen significant advances in our understanding and treatment of multiple myeloma (MM) and its precursor diseases. These advances include gains in knowledge of the underlying pathobiology including molecular and cellular prognostic factors for disease progression. In parallel we have witnessed the availability of novel therapeutics. Together these advances have translated into improvements in long-term clinical benefit and survival in MM. Indeed, it has been shown that patients diagnosed in the last decade have experienced almost doubling of median survival time. We aim to review and give further insight into drug development and novel drug approvals that have revolutionized the treatment of MM.
authors.affiliation: Myeloma program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health and the Office of Hematology and Oncology Products, Food and Drug Administration, Bethesda, MD. Electronic address: kazandjiandg@mail.nih.gov.
authors.forename: Dickran
authors.initials: D
authors.lastname: Kazandjian
authors.affiliation: Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
authors.forename: Ola
authors.initials: O
authors.lastname: Landgren
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017277:Drug Approval; D055808:Drug Discovery; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D061988:Proteasome Inhibitors / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D056572:Histone Deacetylase Inhibitors; D007155:Immunologic Factors; D061988:Proteasome Inhibitors
keywords: Approvals; EMA; FDA; Myeloma; Smoldering